The MUC1-Targeted Silica Nanocarrier (MPPM) for Breast Cancer

#GS-3 #Science & Technology #Biotechnology #Health #Current Events #National

Why in News

Scientists at the Agharkar Research Institute (ARI) in Pune have created a new gene-silencing nanomedicine to treat breast cancer effectively.
This platform called MPPM helps shrink tumors by delivering targeted genetic material directly to cancer cells.

Named the MUC1-Targeted Silica Nanocarrier or MPPM, this engineered nanohybrid platform acts as a vehicle for targeted gene therapy.
The system uses customizable surface chemistry to wrap and carry genetic material safely inside the human body.
A team of Indian researchers from the Nanobioscience Group at ARI Pune developed this advanced platform.

The primary goal of MPPM is to achieve exact gene silencing inside malignant breast cancer cells while lowering overall body toxicity.
It shuts down specific survival pathways that help tumors resist standard treatments, offering a safer option than traditional chemotherapy.

The platform relies on a biodegradable mesoporous silica core that offers high payload capacity and customizable surface structures.
It uses a protamine biopolymer and an MUC1-specific aptamer to lock onto MUC1 receptors found on breast cancer cells, which boosts cellular uptake and reduces side effects.
The dual-action siRNA payload carries small interfering RNA molecules targeting two critical anti-apoptotic genes named MCL-1 and Survivin.
Its structure releases the therapeutic payload only when it encounters the specific chemical environment of the tumor.
Tests on animal models like SCID mice proved that the nanocarrier gathers at the tumor site safely without causing major systemic toxicity.

In MCF-7 breast cancer models, the nanomedicine successfully silenced target genes, caused programmed cell death, and reduced tumor growth.
By targeting MCL-1 and Survivin, it helps overcome resistance to conventional cancer therapies.
The modular design allows doctors to load different siRNA molecules, creating custom gene-silencing treatments for various cancer types.